Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions
Authors
Keywords
-
Journal
Expert Review of Vaccines
Volume 14, Issue 12, Pages 1529-1541
Publisher
Informa UK Limited
Online
2015-10-22
DOI
10.1586/14760584.2015.1099437
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12).
- (2017) K. Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
- (2015) E. J. Small et al. CLINICAL CANCER RESEARCH
- Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
- (2015) D. GuhaThakurta et al. CLINICAL CANCER RESEARCH
- Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC).
- (2015) Edward Samuel James et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells
- (2014) J. Carrasco et al. JOURNAL OF IMMUNOLOGY
- Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer
- (2014) Lawrence Fong et al. JNCI-Journal of the National Cancer Institute
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- ICAM-1 signaling in endothelial cells
- (2014) Charlotte Lawson et al. Pharmacological Reports
- Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model
- (2014) Zineb Belcaid et al. PLoS One
- Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T
- (2014) E J Small et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
- (2013) A. Bahl et al. ANNALS OF ONCOLOGY
- A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
- (2013) Masanori Noguchi et al. BMC CANCER
- The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer
- (2013) Gregory R. Pond et al. EUROPEAN UROLOGY
- Phase III Trials With Docetaxel-Based Combinations for Metastatic Castration-Resistant Prostate Cancer: Time to Learn From Past Experiences
- (2013) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial
- (2013) Paul F. Schellhammer et al. UROLOGY
- Quality of Life After Sipuleucel-T Therapy: Results From a Randomized, Double-blind Study in Patients With Androgen-dependent Prostate Cancer
- (2013) Tomasz M. Beer et al. UROLOGY
- Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
- (2012) Nadeem A. Sheikh et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment
- (2012) J. T. Isaacs et al. CANCER RESEARCH
- Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients
- (2012) S. S. Kwek et al. JOURNAL OF IMMUNOLOGY
- Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
- (2012) M. L. Huber et al. JNCI-Journal of the National Cancer Institute
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- S100A9 Interaction with TLR4 Promotes Tumor Growth
- (2012) Eva Källberg et al. PLoS One
- Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
- (2011) Véronique Corbière et al. CANCER RESEARCH
- Current Vaccination Strategies for Prostate Cancer
- (2011) Steven Joniau et al. EUROPEAN UROLOGY
- Listening to Provenge — What a Costly Cancer Treatment Says about Future Medicare Policy
- (2011) James D. Chambers et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted t-cell epitopes
- (2011) Laura E. Johnson et al. PROSTATE
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer
- (2009) Douglas G. McNeel et al. JOURNAL OF CLINICAL ONCOLOGY
- CD54 is a surrogate marker of antigen presenting cell activation
- (2008) N. A. Sheikh et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started